Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cosmos HealthCOSM -5.08%29 3-Year EBITDA Growth Rate is 52.30% as of Mar. 2026, which is 426% above its 10-year median of 9.95. GuruFocus rates COSM with a GF Score™ of 29/100 and a GF Value™ of $0.35 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 104 Medical Distribution companies, Cosmos Health ranks better than 89.42% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 52.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Cosmos Health was 57.90% per year. The lowest was -274.30% per year. And the median was 9.95% per year.
Cosmos Health (NAS:COSM) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Cosmos Health 3-Year EBITDA Growth Rate Related Terms
COSM vs HKPD, SNYR, YI: 3-Year EBITDA Growth Rate Comparison
For the Medical Distribution subindustry, Cosmos Health's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosmos Health 3-Year EBITDA Growth Rate vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Cosmos Health's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Cosmos Health's 3-Year EBITDA Growth Rate falls into.
Cosmos Health 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 52.30% mean?
Cosmos Health (COSM) has a 3-Year EBITDA Growth Rate of 52.30% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Cosmos Health and its competitors. This is 426% above median its historical median of 9.95. According to the industry distribution chart, Cosmos Health ranks #11 out of 104 companies in the Medical Distribution industry, placing it in the top 10.6%.
Is Cosmos Health's 3-Year EBITDA Growth Rate too high?
Cosmos Health's current 3-Year EBITDA Growth Rate of 52.30% is 426% above median its 10-year median of 9.95. The Medical Distribution industry median 3-Year EBITDA Growth Rate is 6.10. Cosmos Health's value of 52.30% is 757.4% above this industry median. Based on the distribution chart, Cosmos Health ranks #11 out of 104 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Cosmos Health has a GF Score™ of 29/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cosmos Health's 3-Year EBITDA Growth Rate compare to HKPD and SNYR?
According to the Medical Distribution industry distribution chart, Cosmos Health ranks #11 out of 104 companies for 3-Year EBITDA Growth Rate. This places Cosmos Health in the top 11% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 6.10. Cosmos Health's value of 52.30% is 757.4% above this benchmark. While the company's 10-year median is 9.95 vs. the industry median of 6.10, Cosmos Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Distribution company?
The median 3-Year EBITDA Growth Rate among Medical Distribution companies is 6.10, based on 104 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cosmos Health's current 3-Year EBITDA Growth Rate of 52.30% is 757.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Cosmos Health and its competitors. For the Medical Distribution industry, the median 3-Year EBITDA Growth Rate is 6.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosmos Health's current 3-Year EBITDA Growth Rate is 52.30%, which is 426% above median its own 10-year median of 9.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosmos Health stock overvalued right now?
Based on GuruFocus' analysis, Cosmos Health (COSM) is currently considered Possible Value Trap. The stock's GF Value™ is $0.35, compared to a current price of $0.22 — trading 37.5% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 52.30%, which is 426% above median its 10-year median of 9.95 and 757.4% above the Medical Distribution industry median of 6.10. Cosmos Health's overall GF Score™ is 29/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Cosmos Health (COSM), the current 3-Year EBITDA Growth Rate is 52.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosmos Health (COSM) Overvalued in 2026?
Based on GuruFocus' analysis, Cosmos Health stock appears to be undervalued.
The current stock price of $0.22 is trading 37.5% below its estimated GF Value™ of $0.35.
GuruFocus considers Cosmos Health to be Possible Value Trap.
Key valuation signals for COSM:
3-Year EBITDA Growth Rate: 52.30% (426% above median its 10-year median of 9.95)
GF Value™: $0.35 vs. price of $0.22 (37.5% below fair value)
Industry Position: 757.4% above the Medical Distribution median (#11 of 104)
No single metric tells the full story. See the COSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosmos Health Inc is a diversified, vertically integrated healthcare group, owner of proprietary pharmaceutical and nutraceutical brands, generics, manufacturer and distributor of healthcare products, engaged in research & development of medicines and repurposing drugs as well as operator of a telehealth platform. The company has developed its own proprietary branded nutraceutical products, named 'Sky Premium Life' and 'Mediterranation'. Its product portfolio includes generics and over-the-counter pharmaceutical products, medicines, as well as nutraceuticals and biocides. The company's Reportable segments are Wholesale, Pharma manufacturing, and Nutraceutical and pharmaceuticals, with the majority of revenue generated from the Wholesale segment.
29GF Score
Get the complete analysis for COSM
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COSM has been successfully added to your 
